EMV.AX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: October 21, 2025
Report Source: 2025 Annual Report
EMvision Medical Devices Ltd. Stock Analysis EMV.AX
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-12-13. The firm is focused on the development and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. The Company’s primary focus is portable and non-invasive brain scanners, including a bedside device (emu) and an ultra-light weight pre-hospital device (First Responder). Its first indication is in stroke care. Its product pipeline includes portable and non-invasive brain scanners, including a bedside device (emu) and a light weight first responder pre-hospital device. Its First Responder Brain Scanner device is an ultra-light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location. The emu Brain Scanner device detects clinically significant changes, at the bedside, when time matters.
Read More EMvision Medical Devices Ltd (EMV.AX) Chart
Key Statistics of EMvision Medical Devices Ltd (EMV.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD1.76Volume
40.67KP/E Ratio (TTM)
-52 Week Range
Market Cap
178.44MAvg. Volume
9627.40Dividend Yield
-Financial Metrics & Statements of EMvision Medical Devices Ltd (EMV.AX)
FAQ's for EMvision Medical Devices Ltd (EMV.AX)
- According to Musaffa’s Shariah screening methodology, EMvision Medical Devices Ltd (EMV.AX) is currently classified as NOT HALAL as of October 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.